Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence

Bettina R Bonn; Marius Rohde; Martin Zimmermann; David Krieger; Ilske Oschlies; Felix Niggli; Grazyna Wrobel; Andishe Attarbaschi; Gabriele Escherich; Wolfram Klapper; Alfred Reiter; Birgit Burkhardt

doi:10.1182/blood-2012-12-474148

Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence

Standard

Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. / Bonn, Bettina R; Rohde, Marius; Zimmermann, Martin; Krieger, David; Oschlies, Ilske; Niggli, Felix; Wrobel, Grazyna; Attarbaschi, Andishe; Escherich, Gabriele; Klapper, Wolfram; Reiter, Alfred; Burkhardt, Birgit.

in: BLOOD, Jahrgang 121, Nr. 16, 18.04.2013, S. 3153-60.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bonn, BR, Rohde, M, Zimmermann, M, Krieger, D, Oschlies, I, Niggli, F, Wrobel, G, Attarbaschi, A, Escherich, G, Klapper, W, Reiter, A & Burkhardt, B 2013, 'Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence', BLOOD, Jg. 121, Nr. 16, S. 3153-60. https://doi.org/10.1182/blood-2012-12-474148

APA

Bonn, B. R., Rohde, M., Zimmermann, M., Krieger, D., Oschlies, I., Niggli, F., Wrobel, G., Attarbaschi, A., Escherich, G., Klapper, W., Reiter, A., & Burkhardt, B. (2013). Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. BLOOD, 121(16), 3153-60. https://doi.org/10.1182/blood-2012-12-474148

Vancouver

Bonn BR, Rohde M, Zimmermann M, Krieger D, Oschlies I, Niggli F et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. BLOOD. 2013 Apr 18;121(16):3153-60. https://doi.org/10.1182/blood-2012-12-474148

Bibtex

@article{e1ba9fcf76a142028cfdfde89ba1572d,

title = "Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence",

abstract = "Probability of event-free survival (pEFS) in pediatric T-cell lymphoblastic lymphoma is about 80%, whereas survival in relapsed patients is very poor. No stratification criteria have been established so far. Recently, activating NOTCH1 mutations were reported to be associated with favorable prognosis, and loss of heterozygosity at chromosome 6q (LOH6q) was reported to be associated with increased relapse risk. The current project was intended to evaluate the prognostic effect of these markers. Mutations in hot spots of NOTCH1 and FBXW7 were analyzed in 116 patients. Concerning LOH6q status, 118 patients were investigated, using microsatellite marker analysis, in addition to an earlier reported cohort of 99 available patients. Ninety-two cases were evaluable for both analyses. All patients were treated with T-cell lymphoblastic lymphoma-Berlin-Frankfurt-M{\"u}nster group (BFM)-type treatment. LOH6q was observed in 12% of patients (25/217) and associated with unfavorable prognosis (pEFS 27% ± 9% vs 86% ± 3%; P < .0001). In 60% (70/116) of the patients, NOTCH1 mutations were detected and associated with favorable prognosis (pEFS 84% ± 5% vs 66% ± 7%; P = .021). Interestingly, NOTCH1 mutations were rarely observed in patients with LOH in 6q16. Both prognostic markers will be used as stratification criteria in coming Non-Hodgkin Lymphoma-BFM trials.",

keywords = "Adolescent, Cell Cycle Proteins, Child, Chromosomes, Human, Pair 6, Cohort Studies, DNA Mutational Analysis, F-Box Proteins, Female, Genetic Variation, Humans, Incidence, Loss of Heterozygosity, Lymphoma, T-Cell, Male, Mutation, Prognosis, Receptor, Notch1, Ubiquitin-Protein Ligases",

author = "Bonn, {Bettina R} and Marius Rohde and Martin Zimmermann and David Krieger and Ilske Oschlies and Felix Niggli and Grazyna Wrobel and Andishe Attarbaschi and Gabriele Escherich and Wolfram Klapper and Alfred Reiter and Birgit Burkhardt",

year = "2013",

month = apr,

day = "18",

doi = "10.1182/blood-2012-12-474148",

language = "English",

volume = "121",

pages = "3153--60",

journal = "BLOOD",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "16",

}

RIS

TY - JOUR

T1 - Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence

AU - Bonn, Bettina R

AU - Rohde, Marius

AU - Zimmermann, Martin

AU - Krieger, David

AU - Oschlies, Ilske

AU - Niggli, Felix

AU - Wrobel, Grazyna

AU - Attarbaschi, Andishe

AU - Escherich, Gabriele

AU - Klapper, Wolfram

AU - Reiter, Alfred

AU - Burkhardt, Birgit

PY - 2013/4/18

Y1 - 2013/4/18

N2 - Probability of event-free survival (pEFS) in pediatric T-cell lymphoblastic lymphoma is about 80%, whereas survival in relapsed patients is very poor. No stratification criteria have been established so far. Recently, activating NOTCH1 mutations were reported to be associated with favorable prognosis, and loss of heterozygosity at chromosome 6q (LOH6q) was reported to be associated with increased relapse risk. The current project was intended to evaluate the prognostic effect of these markers. Mutations in hot spots of NOTCH1 and FBXW7 were analyzed in 116 patients. Concerning LOH6q status, 118 patients were investigated, using microsatellite marker analysis, in addition to an earlier reported cohort of 99 available patients. Ninety-two cases were evaluable for both analyses. All patients were treated with T-cell lymphoblastic lymphoma-Berlin-Frankfurt-Münster group (BFM)-type treatment. LOH6q was observed in 12% of patients (25/217) and associated with unfavorable prognosis (pEFS 27% ± 9% vs 86% ± 3%; P < .0001). In 60% (70/116) of the patients, NOTCH1 mutations were detected and associated with favorable prognosis (pEFS 84% ± 5% vs 66% ± 7%; P = .021). Interestingly, NOTCH1 mutations were rarely observed in patients with LOH in 6q16. Both prognostic markers will be used as stratification criteria in coming Non-Hodgkin Lymphoma-BFM trials.

AB - Probability of event-free survival (pEFS) in pediatric T-cell lymphoblastic lymphoma is about 80%, whereas survival in relapsed patients is very poor. No stratification criteria have been established so far. Recently, activating NOTCH1 mutations were reported to be associated with favorable prognosis, and loss of heterozygosity at chromosome 6q (LOH6q) was reported to be associated with increased relapse risk. The current project was intended to evaluate the prognostic effect of these markers. Mutations in hot spots of NOTCH1 and FBXW7 were analyzed in 116 patients. Concerning LOH6q status, 118 patients were investigated, using microsatellite marker analysis, in addition to an earlier reported cohort of 99 available patients. Ninety-two cases were evaluable for both analyses. All patients were treated with T-cell lymphoblastic lymphoma-Berlin-Frankfurt-Münster group (BFM)-type treatment. LOH6q was observed in 12% of patients (25/217) and associated with unfavorable prognosis (pEFS 27% ± 9% vs 86% ± 3%; P < .0001). In 60% (70/116) of the patients, NOTCH1 mutations were detected and associated with favorable prognosis (pEFS 84% ± 5% vs 66% ± 7%; P = .021). Interestingly, NOTCH1 mutations were rarely observed in patients with LOH in 6q16. Both prognostic markers will be used as stratification criteria in coming Non-Hodgkin Lymphoma-BFM trials.

KW - Adolescent

KW - Cell Cycle Proteins

KW - Child

KW - Chromosomes, Human, Pair 6

KW - Cohort Studies

KW - DNA Mutational Analysis

KW - F-Box Proteins

KW - Female

KW - Genetic Variation

KW - Humans

KW - Incidence

KW - Loss of Heterozygosity

KW - Lymphoma, T-Cell

KW - Male

KW - Mutation

KW - Prognosis

KW - Receptor, Notch1

KW - Ubiquitin-Protein Ligases

U2 - 10.1182/blood-2012-12-474148

DO - 10.1182/blood-2012-12-474148

M3 - SCORING: Journal article

C2 - 23396305

VL - 121

SP - 3153

EP - 3160

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 16

ER -